Document is current
Any future updates will be listed below
-
Authors
Canales-Siguero, M. D. https://orcid.org/0000-0003-1192-2855
García-Muñoz, C. https://orcid.org/0000-0003-3180-4952
Caro-Teller, J. M. https://orcid.org/0000-0002-3043-653X
Piris-Borregas, S.
Martín-Aragón, S. https://orcid.org/0000-0003-1612-2726
Ferrari-Piquero, J. M.
Moral-Pumarega, M. T. https://orcid.org/0000-0003-0766-7169
Pallás-Alonso, C. R. https://orcid.org/0000-0001-9710-8162
- License Information
-
More Information
Article History
Received: 28 June 2024
Accepted: 7 February 2025
First Online: 18 February 2025
Declarations
:
: The studies involving humans were approved by Comité de Ética de la Investigación con medicamentos (CEIm) del Hospital Universitario 12 de Octubre. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation was not required from the participants or the participants’ legal guardians/next of kin because The Research Ethics Committee of the Hospital 12 de Octubre considered that the patient’s informed consent was not required as this was a project to improve the quality of care. In this study, the review of treatments by a clinical pharmacist was considered an improvement in care to reduce prescription errors; only the patient can benefit from this measure. In addition, any prescribing errors that were found were reported to the patient’s treating physician and the treating physician made the treatment decision, which is the usual procedure.
: Not applicable.
: Not applicable.
: The authors declare no competing interests.
